Form 8-K - Current report:
SEC Accession No. 0001193125-24-256014
Filing Date
2024-11-12
Accepted
2024-11-12 16:30:59
Documents
13
Period of Report
2024-11-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d853506d8k.htm   iXBRL 8-K 26385
  Complete submission text file 0001193125-24-256014.txt   145775

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA teva-20241105.xsd EX-101.SCH 2878
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20241105_lab.xml EX-101.LAB 17168
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20241105_pre.xml EX-101.PRE 10807
16 EXTRACTED XBRL INSTANCE DOCUMENT d853506d8k_htm.xml XML 3614
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 241448945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)